Novavax Inc
(WBO:NVAX)
€
9.276
-0.09 (-0.96%)
Market Cap: 1.49 Bil
Enterprise Value: 734.28 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 47/100 Novavax Inc at H C Wainwright Global Investment Conference (Virtual)- Pre-Recorded Transcript
Sep 13, 2021 / 11:00AM GMT
Vernon Tolentino Bernardino
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good day, everyone, and thank you for joining the H.C. Wainwright 23rd Annual Global Investment Conference. My name is Vernon Bernardino, and I'm a senior analyst at H.C. Wainwright. While we are in a virtual format this year, we're confident we can provide value to you with over 850 companies presenting and available for one-on-one meetings. We recommend you meet with all of our companies as each has a special story that you should hear.
With that said, I'd like to introduce to -- you to a special company, a company called Novavax, which is developing next-generation vaccines. With us today are President of R&D, Greg Glenn; and Chief Commercial Officer/Chief Business Officer, John Trizzino. Welcome, gentlemen.
John Joseph Trizzino;Gregory M. Glenn
Novavax, Inc. - Executive VP and Chief Business & Commercial Officer;Novavax, Inc. - President of Research &
Thank you.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot